Source: Molecular Oncology. Conference titles: Workshop on Cancer Research, Healthcare and Prevention: Structuring translational research to increase innovation and reduce inequalities. Unidade: IFSC
Subjects: ONCOLOGIA, PREVENÇÃO DE DOENÇAS
ABNT
RINGBORG, Ulrik e BAGNATO, Vanderlei Salvador. Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities. Molecular Oncology. Hoboken: Instituto de Física de São Carlos, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/1878-0261.70179. Acesso em: 24 abr. 2026. , 2026APA
Ringborg, U., & Bagnato, V. S. (2026). Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities. Molecular Oncology. Hoboken: Instituto de Física de São Carlos, Universidade de São Paulo. doi:10.1002/1878-0261.70179NLM
Ringborg U, Bagnato VS. Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities [Internet]. Molecular Oncology. 2026 ; 20( 2): 191-221.[citado 2026 abr. 24 ] Available from: https://doi.org/10.1002/1878-0261.70179Vancouver
Ringborg U, Bagnato VS. Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities [Internet]. Molecular Oncology. 2026 ; 20( 2): 191-221.[citado 2026 abr. 24 ] Available from: https://doi.org/10.1002/1878-0261.70179

